Werewolf Therapeutics (NASDAQ:HOWL) Raised to Sell at Wall Street Zen

Posted by Geri Gentry on Aug 3rd, 2026

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a report released on Saturday.

Separately, Weiss Ratings downgraded Werewolf Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, June 16th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.75.

View Our Latest Report on Werewolf Therapeutics

Werewolf Therapeutics Price Performance

HOWL stock opened at $0.35 on Friday. The stock has a market capitalization of $17.16 million, a P/E ratio of -0.46 and a beta of 0.29. The business has a 50-day moving average of $0.39 and a 200-day moving average of $0.60. Werewolf Therapeutics has a fifty-two week low of $0.27 and a fifty-two week high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL – Get Free Report) last posted its quarterly earnings data on Friday, July 31st. The company reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.36. The firm had revenue of $21.00 million for the quarter, compared to the consensus estimate of $21.00 million. Equities analysts expect that Werewolf Therapeutics will post -1.08 EPS for the current year.

Insider Transactions at Werewolf Therapeutics

In other news, major shareholder Ra Capital Management, L.P. sold 416,911 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $0.35, for a total value of $145,918.85. Following the completion of the transaction, the insider owned 303,719 shares in the company, valued at $106,301.65. This trade represents a 57.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Luke Evnin sold 305,741 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $0.70, for a total value of $214,018.70. Following the completion of the transaction, the director owned 1,273,008 shares of the company’s stock, valued at $891,105.60. The trade was a 19.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 3,586,707 shares of company stock valued at $1,717,354. Company insiders own 23.60% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of HOWL. Susquehanna International Group LLP increased its position in shares of Werewolf Therapeutics by 16.9% during the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock worth $183,000 after purchasing an additional 13,439 shares during the last quarter. Vontobel Holding Ltd. raised its stake in shares of Werewolf Therapeutics by 66.7% during the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares in the last quarter. Regal Investment Advisors LLC boosted its holdings in shares of Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after buying an additional 25,389 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock valued at $2,321,000 after buying an additional 25,882 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new position in shares of Werewolf Therapeutics in the second quarter valued at $48,000. 64.84% of the stock is currently owned by institutional investors.

About Werewolf Therapeutics

(Get Free Report)

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.